Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

David Cairns

Has grant

Professor of Clinical Trials Research

University of Leeds

United Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Recent Grants

Grant: Close

Novel statistical methods for the design and analysis of proteomic experiments for biomarker discovery

Open Date: 2009-06-30

Close Date: 2013-06-29

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (30)

Timon Vandamme

Assistant Professor

University of Antwerp

BELGIUM

View details

Nicholas West

University of Leeds School of Medicine

UNITED KINGDOM

View details

Richard Houlston

Professor

Institute of Cancer Research Sutton

UNITED KINGDOM

View details

Heike I Grabsch

Professor

University of Leeds

UNITED KINGDOM

View details

Andrew Clegg

Professor of Geriatric Medicine

University of Leeds

UNITED KINGDOM

View details

Sara De Dosso

Università della Svizzera Italiana (USI)

SWITZERLAND

View details

Philip Law

Institute of Cancer Research

UNITED KINGDOM

View details

Clara Montagut Viladot

Head Gastrointestinal Cancer Section

Hospital del Mar

SPAIN

View details

Bryony Dawkins

Lectuer in Health Economics

University of Leeds

UNITED KINGDOM

View details

Simon Mitchell

University of Sussex

UNITED KINGDOM

View details

Ian White

Professor at Institute of Clinical Trials and Methodology (ICTM)

University College London

UNITED KINGDOM

View details

Martin Kaiser

Professor of Haematology

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

UNITED KINGDOM

View details

Gordon Cook

University of Leeds

UNITED KINGDOM

View details

MICHELE CAVO

University of Bologna

ITALY

View details

Derek Magee

Associate Professor

University of Leeds

UNITED KINGDOM

View details

Jenny Seligmann

University of Leeds

UNITED KINGDOM

View details

Richard Adams

Professor

Cardiff University

UNITED KINGDOM

View details

David Allsup

Professor

Hull York Medical School

UNITED KINGDOM

View details

Suzanne Richards

Head of Unit

University of Leeds

UNITED KINGDOM

View details

Remond J.A. Fijneman

Principal Investigator

The Netherlands Cancer Institute

NETHERLANDS

View details

Catherine Olivier

Head of Trial Management

University of Leeds

UNITED KINGDOM

View details

Jesus F. San Miguel

SPAIN

View details

Emerik Osterlund

Uppsala Universitet Farmaceutiska fakulteten

SWEDEN

View details

Ruth Langley

University College London

UNITED KINGDOM

View details

Gabor Liposits

Aarhus University

DENMARK

View details

Karen-Lise Garm Spindler

Professor, Chief Consultant

Aarhus University Hospital

DENMARK

View details

Jamie Stokes

University of Oxford

UNITED KINGDOM

View details

Pia Osterlund

Karolinska University Hospital

SWEDEN

View details

Nancy Fernandes da Silva

Head of Clinical Trial Management

University of Leeds

UNITED KINGDOM

View details

Marc S. Raab

University Hospital Heidelberg

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Cairns

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (20)

The density of tumour infiltrating lymphocytes in oesophago-gastric cancer varies with disease stage, geographical region and treatment: a post hoc analysis of nine phase III clinical trials

Safety and efficacy of neoadjuvant chemotherapy (NAC) in older patients with locally advanced colon cancer (LACC): Results from FOxTROT 1 and the FOxTROT 2 safety cohort population.

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

Clinical, cytogenetic, and germline genetic determinants of arterial thromboembolism in IMiD-treated multiple myeloma

OA-04 A Novel Analytical Approach to Addressing the Challenge of Assessing Overall Survival in Myeloma Trials in the Context of a Rapidly Evolving Treatment Landscape

OA-19 Double Hit Ultra-High Risk Myeloma Treated With Isa-VRD Plus Cyclophosphamide Induction and Isa-VRD Consolidation: QoL Analysis of the UKMRA RADAR Trial in Newly Diagnosed Transplant Eligible Patients

PA-152 Double-Hit Ultra-High-Risk Myeloma Treated with Isa-VRDc Induction and Isa-VRD Consolidation: Subanalysis of the UKMRA RADAR Trial in Newly Diagnosed Transplant-Eligible Patients

Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis

Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

[Abstract] Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings

How should overall survival be analysed in randomised clinical trials in cancer if participants receive subsequent treatment lines? A stakeholder consultation

Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia

MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial

Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.

Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Collaborators (30)

Timon Vandamme

Nicholas West

Richard Houlston

Heike I Grabsch

Andrew Clegg

Sara De Dosso

Philip Law

Clara Montagut Viladot

Bryony Dawkins

Simon Mitchell

Ian White

Martin Kaiser

Gordon Cook

MICHELE CAVO

Derek Magee

Jenny Seligmann

Richard Adams

David Allsup

Suzanne Richards

Remond J.A. Fijneman

Catherine Olivier

Jesus F. San Miguel

Emerik Osterlund

Ruth Langley

Gabor Liposits

Karen-Lise Garm Spindler

Jamie Stokes

Pia Osterlund

Nancy Fernandes da Silva

Marc S. Raab

Make your next move.